According to a commentary, for many clinicians, the most anticipated data from this study was not the randomised efficacy comparison of chemotherapy with or without bevacizumab, but rather the retrospective comparison of the cytotoxic doublets used. It notes that although the results of E1505 cannot be celebrated, the trial's results can direct clinical efforts away from bevacizumab and cytotoxic regimen choice. It discusses trials of durvalumab, erlotinib, crizotinib and nivolumab, which might provide further direction to improved treatment regimens for patients with non-metastatic non-small-cell lung cancer.